It is most appropriate that the journal, Biomolecular Detection and Quantification introduces the concepts of metrology and standards and their importance to quantitative molecular methodologies in ensuring their accuracy, the robustness of research results and the development of reliable and reproducible methods for diagnosis of disease.
International comparisons of measurement methods across laboratories, and the establishment of calibration hierarchies, permit traceable measurement results to be obtained, ensuring compatible measurement results through both space and time. Such comparison exercises are organized by the Consultative Committee for Metrology in Chemistry and Biology (CCQM) of the Bureau International des Poids et Mesures (BIPM) and in particular, for Biomolecular Detection and Quantification, the working Groups on Nucleic, Protein and Cell analysis. The activities of these groups are an extension of the global measurement system that includes the International System of Units (SI), which represents an internationally recognized system based on standards of long-term stability, and by the use traceable measurements provides an international infrastructure for realizing comparable measurements.
Gene expression biomarker profiling can distinguish between disease states (e.g. cancer subtyping) or predict how tumours will react to particular treatments (stratified medicine) and therefore offers considerable potential as an exploitable technology for disease diagnosis and prognosis. However, RNA measurement is challenging and complicated by difficulties associated with the robustness and comparability of the techniques used to analyse these molecules and the lack of commonly applied universal standards.
The international comparison CCQM-P103.1 (Gene expression biomarker profiling, coordinated by LGC), was designed to address these issues and the equivalence of measurement results from different techniques at National Metrology Institutes, and follows on from the 2011 P103 study using a single RNA transcript to underpin work to distinguish normal from diseased cells. In study P103.1, the accuracy and inter-laboratory reproducibility of RNA biomarker measurements was assessed by comparing multiple RNA copy number ratios and associated measurement uncertainties of a panel of synthetic and endogenous transcripts. The majority of reported results (>90%) were in agreement with the assigned values, with close to 100% concordance observed for laboratories performing a validated RT-qPCR protocol. The datasets provide evidence that the approaches used demonstrate the accuracy and precision predicted for the measurement methods and are consistent with the measurement uncertainty calculations for RT-qPCR-based copy number ratio measurements.
Pilot study CCQM-P103.1 sets a benchmark in terms of the technical performance of analytical methods for mRNA quantification and provides a foundation for the development of a reference system to support molecular diagnostic tests utilising changes in gene expression. The future development of the capabilities of metrology and reference laboratories to perform independent certification of reference materials and internal controls for gene expression tests is expected to enable verification of the analytical validity of molecular tests for cancer prognosis and personalised prediction of treatment efficacy and support regulation of novel in vitro diagnostic devices. 
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